Endocrine Abstracts

Purpose: The efficacy and safety of RAD, an mTOR inhibitor, in patients with well differentiated metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NET).Material and methods: We studied seven male patients (mean age 55 years, range 36–75) with well differentiated non functioning stage IV GEP-NETs (five pancreatic, one hindgut carcinoid, and one NET of unknown primary). All received RAD 10 mg/day in combination with long acting octerotide 3...